Please login to read the full text of the article.
If you have no account yet, please register now.
Posted on
Previous Article
« No need to adjust rivaroxaban dose for overweight heart disease patients Next Article
Breast cancer overtakes lung as most common cancer-WHO »
« No need to adjust rivaroxaban dose for overweight heart disease patients Next Article
Breast cancer overtakes lung as most common cancer-WHO »
Related Articles
October 26, 2021
NSCLC survival improving in U.S.; older patients undertreated

April 18, 2021
Phase III ADAURA Trial: CNS Recurrences slashed for NSCLC
© 2021 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy